Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Ludwig Enterprises Begins PCR Validation Test Process

By: ACCESSWIRE

November 07, 2024 at 04:00 AM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Final step before the full launch of breast cancer screening program, Revealia™

SPARKS, NV / ACCESSWIRE / November 7, 2024 / Ludwig Enterprises, Inc. (OTC PINK:LUDG), a leading USA-based biotechnology company (the "Company"), has retained an independent lab in Florida that will conduct a third-party validation process for the Company's PCR (Polymerase Chain Reaction) breast cancer screening program, Revealia™. Once the validation protocols have been established and testing completed, Revealia™ will begin its nationwide launch.

Assay optimization and validation are essential, even when using assays that have been predesigned and commercially obtained. Optimization is required to ensure that the assay is as sensitive as required and specific to the target of interest. This process ensures that they are sensitive enough to detect indications of rare diseases or specific biomarkers and identify the relevant targets. Assay conditions must be optimized to detect all targets - universally. Validation provides the data required to justify the continued use of the assay in further research projects.

The validation process often takes 6-8 weeks to finalize, but the Company will work with the contracted lab to achieve a reduced timeline of 5-6 weeks, potentially allowing for a launch of Revealia™ in the 4^th quarter of 2024.

"We are very excited to begin this final leg towards the launch of Revealia™. We have increased the sensitivity and predictability of the screening panel by using PCR evaluation of 6 mRNA biomarkers," stated Marvin S. Hausman MD, CSO of the Company. "Our innovative and non-invasive screening test empowers people to be proactive with their medical care and potentially detect health issues early on."

About Ludwig Enterprises, Inc.
Ludwig Enterprises, Inc. (which is to change its name to Revealia, Inc.), a biotech and healthcare holding company, is a global - innovator in mRNA genomics and machine learning AI technology. Our mission is to identify, monitor, and create solutions to -mitigate chronic inflammation, the causative agent of illnesses such as cancer and heart disease, which are responsible for more than 50% of deaths worldwide.

For more information, please visit: http://www.ludwigent.com

About Revealia™
Revealia™ is a breast cancer screening test that utilizes a proprietary mRNA microarray to establish a personalized inflammatory index that provides a patient with reliable information that can assist in their healthcare medical decisions. - Artificial intelligence (AI) is used to determine a risk score, which is derived from a specific array of inflammatory biomarkers and comparing it to a database of previously analyzed patients.

For more information, please visit: www.revealia.com

SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition.

CONTACT:
Ludwig Enterprises, Inc.
www.ludwigent.com
Twitter: @LUDG_inc

Investor Relations
Resources Unlimited NW LLC
Mike Sheikh, Investor Relations
mike@resourcesunlimtedllc.com

Contact Information
Mike Sheikh
Investor Relations
mike@resourcesunlimtedllc.com

SOURCE: Ludwig Enterprise, Inc.

View the original press release on accesswire.com

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

Symbol	Price	Change (%)
AMZN	237.50	+0.00 (0.00%)
AAPL	295.95	+0.00 (0.00%)
AMD	512.48	+0.00 (0.00%)
BAC	56.53	+0.00 (0.00%)
GOOG	362.10	+0.00 (0.00%)
META	567.58	+0.00 (0.00%)
MSFT	378.91	+0.00 (0.00%)
NVDA	204.65	+204.63 (1003086.27%)
ORCL	183.53	+0.00 (0.00%)
TSLA	396.38	+0.00 (0.00%)